{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T06:24:37Z","timestamp":1763101477677,"version":"3.45.0"},"reference-count":36,"publisher":"Tech Science Press","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OR"],"published-print":{"date-parts":[[2025]]},"DOI":"10.32604\/or.2024.056256","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T04:24:07Z","timestamp":1729484647000},"page":"675-685","source":"Crossref","is-referenced-by-count":1,"title":["Dibenzo [a, c] phenazin-11-yl(phenyl) methanone (SBLJ23), a novel selective inhibitor targeting JAK2<sup>V617F<\/sup> mutation in myeloproliferative neoplasms"],"prefix":"10.32604","volume":"33","author":[{"given":"MOHAMMAD","family":"ABOHASSAN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MESFER MOHAMMAD AL","family":"SHAHRANI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SARAH KHALED","family":"ALOUDA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PRASANNA","family":"RAJAGOPALAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"17807","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"F1000 Faculty Rev-700","DOI":"10.12688\/f1000research.8081.1","article-title":"Recent advances in understanding myelofibrosis and essential thrombocythemia","volume":"5","author":"Vainchenker","year":"2016","journal-title":"F1000Research"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.3390\/ijms23094573","article-title":"Molecular pathogenesis of myeloproliferative neoplasms: From molecular landscape to therapeutic implications","volume":"23","author":"Morsia","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.12688\/f1000research.13167.1","article-title":"JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders","volume":"7","author":"Vainchenker","year":"2018","journal-title":"F1000Research"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/0888-7543(87)90031-0","article-title":"Further mapping of markers around the centromere of human chromosome 19","volume":"1","author":"Brook","year":"1987","journal-title":"Genomics"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1158\/1078-0432.CCR-12-0284","article-title":"Molecular pathways: Jak\/STAT pathway: Mutations, inhibitors, and resistance","volume":"19","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Clinical Cancer Research"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.exer.2005.08.014","article-title":"Mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3 kinase (PI3K) pathways differently regulate retinal pigment epithelial cell-mediated collagen gel contraction","volume":"82","author":"Bando","year":"2006","journal-title":"Experimental Eye Research"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunological Reviews"},{"key":"ref8","first-page":"184","article-title":"The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective","volume":"1","author":"Staerk","year":"2012","journal-title":"JAKSTAT"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.clml.2011.04.002","article-title":"BCR-ABL1\u2014negative myeloproliferative neoplasms: A review of molecular biology, diagnosis, and treatment","volume":"11","author":"Vakil","year":"2011","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.2174\/092986711797379267","article-title":"A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: The road not taken","volume":"18","author":"Gnanasambandan","year":"2011","journal-title":"Current Medicinal Chemistry"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12943-023-01929-1","article-title":"JAK\/STAT in leukemia: A clinical update","volume":"23","author":"Liang","year":"2024","journal-title":"Molecular Cancer"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nsmb.2348","article-title":"Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F","volume":"19","author":"Bandaranayake","year":"2012","journal-title":"Nature Structural & Molecular Biology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.3390\/jcm9082334","article-title":"The role of inflammation and inflammasome in myeloproliferative disease","volume":"9","author":"Longhitano","year":"2020","journal-title":"Journal of Clinical Medicine"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2217\/fon.11.81","article-title":"Ruxolitinib: A new JAK1\/2 inhibitor that offers promising options for treatment of myelofibrosis","volume":"7","author":"Ostojic","year":"2011","journal-title":"Future Oncology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","article-title":"Janus kinase inhibitors in autoimmune diseases","volume":"72","author":"O\u2019Shea","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/ph15010048","article-title":"Jakinibs of all trades: Inhibiting cytokine signaling in immune-mediated pathologies","volume":"15","author":"Alexander","year":"2021","journal-title":"Pharmaceuticals"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1320092","DOI":"10.3389\/fendo.2024.1320092","article-title":"Identification of inhibitors from a functional food-based plant Perillae Folium against hyperuricemia via metabolomics profiling, network pharmacology and all-atom molecular dynamics simulations","volume":"15","author":"Wu","year":"2024","journal-title":"Frontiers in Endocrinology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","article-title":"gmx_MMPBSA: A new tool to perform end-state free energy calculations with GROMACS","volume":"17","author":"Vald\u00e9s-Tresanco","year":"2021","journal-title":"Journal of Chemical Theory and Computation"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"305","DOI":"10.32604\/or.2022.025187","volume":"29","author":"Tobeigei","year":"2021","journal-title":"Oncology Research"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1021\/acschembio.8b00722","article-title":"Discovery and structural characterization of ATP-Site ligands for the wild-type and V617F mutant JAK2 pseudokinase domain","volume":"14","author":"McNally","year":"2019","journal-title":"ACS Chemical Biology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"103458","DOI":"10.1016\/j.sjbs.2022.103458","article-title":"Multi-targeted molecular docking, pharmacokinetics, and drug-likeness evaluation of coumarin based compounds targeting proteins involved in development of COVID-19","volume":"29","author":"Mun","year":"2022","journal-title":"Saudi Journal of Biological Sciences"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3390\/biomedicines11030716","article-title":"Computational and preclinical analysis of 2-(4-methyl)benzylidene-4,7-dimethyl Indan-1-one (IPX-18): A novel arylidene indanone small molecule with anti-inflammatory activity via NF-\u03baB and Nrf2 signaling","volume":"11","author":"Gahtani","year":"2023","journal-title":"Biomedicines"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.32604\/or.2022.03539","article-title":"Anticancer efficacy of 3-(4-isopropyl) benzylidene-8-ethoxy, 6-methyl, chroman-4-one (SBL-060), a novel, dual, estrogen receptor-Akt kinase inhibitor in acute myeloid leukemia cells","volume":"29","author":"Shahrani","year":"2021","journal-title":"Oncology Research"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrc3237","article-title":"Combining immunotherapy and targeted therapies in cancer treatment","volume":"12","author":"Vanneman","year":"2012","journal-title":"Nature Reviews Cancer"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10822-022-00466-1","article-title":"Insight into the mechanism of molecular recognition between human Integrin-Linked Kinase and Cpd22 and its implication at atomic level","volume":"36","author":"Garc\u00eda-Mar\u00edn","year":"2022","journal-title":"Journal of Computer-Aided Molecular Design"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"18326","DOI":"10.1038\/s41598-020-75020-w","article-title":"Structural modeling of GSK3\u03b2 implicates the inactive (DFG-out) conformation as the target bound by TDZD analogs","volume":"10","author":"Balasubramaniam","year":"2020","journal-title":"Scientific Reports"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"113675","DOI":"10.1016\/j.ejmech.2021.113675","article-title":"Antitumor properties of novel sesquiterpene lactone analogs as NF\u03baB inhibitors that bind to the IKK\u03b2 ubiquitin-like domain (ULD)","volume":"224","author":"Penthala","year":"2021","journal-title":"European Journal of Medicinal Chemistry"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells","volume":"17","author":"Mullally","year":"2010","journal-title":"Cancer Cell"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3390\/diseases6040085","article-title":"Cell-based methods for determination of efficacy for candidate therapeutics in the clinical management of cancer","volume":"6","author":"Gordon","year":"2018","journal-title":"Diseases"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1182\/blood-2009-03-209544","article-title":"Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells","volume":"115","author":"Will","year":"2010","journal-title":"Blood"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/25785826.2022.2139317","article-title":"Recent progress of JAK inhibitors for hematological disorders","volume":"46","author":"Kirito","year":"2023","journal-title":"Immunological Medicine"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"26834","DOI":"10.18632\/oncotarget.25515","article-title":"Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2","volume":"9","author":"Ishida","year":"2018","journal-title":"Oncotarget"},{"key":"ref33","first-page":"284","volume":"20","author":"Zhang","year":"2020","journal-title":"Experimental and Therapeutic Medicine"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"671138","DOI":"10.3389\/fphar.2021.671138","volume":"12","author":"Xu","year":"2021","journal-title":"Frontiers in Pharmacology"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Barnum, K. J., O\u2019Connell, M. J. (2014). Cell cycle regulation by checkpoints. In: Noguchi, E., Gadaleta, M. (Eds.), Cell cycle control. Methods in molecular biology, vol. 1170, pp. 29\u201340. New York, NY: Humana Press.","DOI":"10.1007\/978-1-4939-0888-2_2"},{"key":"ref36","first-page":"945","article-title":"Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention","volume":"8","author":"Buettner","year":"2002","journal-title":"Clinical Cancer Research"}],"container-title":["Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.techscience.cn\/files\/or\/2025\/TSP_OR-33-3\/OncolRes-33-03-56256\/OncolRes-33-56256.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T06:22:01Z","timestamp":1763101321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v33n3\/59643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.32604\/or.2024.056256","relation":{},"ISSN":["1555-3906"],"issn-type":[{"type":"electronic","value":"1555-3906"}],"subject":[],"published":{"date-parts":[[2025]]}}}